Dexcom: Positive Catalysts Ahead To Support Growth

Willie B. Thomas/DigitalVision via Getty Images Investment action I recommended a buy rating for Dexcom (NASDAQ:DXCM) when I wrote about it during October last year, as the 3Q23 results gave me further confidence in the business's positive outlook. The share price has rallied strongly post-my update, back to as high as DXCM’s 1-year all-time high of $142 (~10% below my target price). Based on my current outlook and analysis, I recommend a buy rating. My key update to my thesis is that DXCM should contin ...